Preliminary results of a prospective assessment of androgen receptor splice variants in mCRPC patients undergoing androgen receptor targeted agents.

Giulio Francolini,Mauro Loi,Beatrice Detti,Monica Mangoni,Isacco Desideri,Cristina Muntoni,Lucia Pia Ciccone,Michele Aquilano,Pamela Pinzani,Francesca Salvianti,Sara Lucidi,Matteo Mariotti,Pietro Garlatti,Giulia Salvatore,Mariangela Sottili,Lorenzo Livi

Preliminary results of a prospective assessment of androgen receptor splice variants in mCRPC patients undergoing androgen receptor targeted agents.

2020

Giulio Francolini
Mauro Loi
Beatrice Detti
Monica Mangoni
Isacco Desideri
Cristina Muntoni
Lucia Pia Ciccone
Michele Aquilano
Pamela Pinzani
Francesca Salvianti
Sara Lucidi
Matteo Mariotti
Pietro Garlatti
Giulia Salvatore
Mariangela Sottili
Lorenzo Livi

246Background: Different treatment options for metastatic castrate resistant prostate cancer (mCRPC) are currently available, including Androgen Receptor Targeted Agents (ARTA) and Taxane based che...

Keywords:

splice
Androgen receptor
Cancer research
Pathology
Medicine
Taxane
Internal medicine
treatment options
Oncology
Castrate-resistant prostate cancer

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations